Litigation Details for Gilead Sciences Inc. v. Abbvie Inc. (D. Del. 2013)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Gilead Sciences Inc. v. Abbvie Inc. (D. Del. 2013)
Docket | See Plans and Pricing | Date Filed | 2013-12-18 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
Jury Demand | Plaintiff | Referred To | |
Patents | 7,964,580; 8,088,368; 8,273,341; 8,334,270; 8,466,159; 8,492,386; 8,580,765; 8,680,106; 8,685,984 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Gilead Sciences Inc. v. Abbvie Inc.
Details for Gilead Sciences Inc. v. Abbvie Inc. (D. Del. 2013)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2015-11-03 | 236 | the asserted claims of U.S. Patent Nos. 8,466,159 (the'" 159 Patent") and 8,492,386 (the … ORDER CONSTRUING THE TERMS OF U.S. PATENT NOs. 8,466,159 & 8,492,386. Signed by Judge Gregory M. … ORDER CONSTRUING THE TERMS OF U.S. PATENT NOs. 8,466,159 & 8,492,386 After having considered…the '"386 Patent"): The term "treatment for HCV" is construed to have its…language of the claim in construing the terms of a patent. Vitronics Corp. v. Conceptronic, Inc., 90 F.3d | External link to document | |
2014-04-10 | 32 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,466,159 B2; US 8,492,386 …18 December 2013 1:13-cv-02034-GMS Patent Plaintiff District Court, D. | External link to document | |
2014-04-10 | 33 | States patent laws. Both PSI-7977 and GS-5885 are protected by United States Patents Nos.7,964,580, 8,334,270…protected by several United States patents, including U.S. Patent Nos. 7,964,580, 8,334,270, and 8,580,765. …violating the U.S. Patent Law. Gilead Pharmasset LLC owns U.S. Patent No. 7,964,580, which covers PSI…including, among others U.S. Patent No. 7,964,580 B2 (“the Gilead ’580 patent”) and U.S. …2690 limited to the following issued U.S. Patents: 7,964,580, 8,334,270, and 8,580,765 (PSI/GS-7977 - | External link to document | |
2013-12-18 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,466,159 B2; US 8,492,386 …18 December 2013 1:13-cv-02034-GMS Patent Plaintiff District Court, D. | External link to document | |
2015-01-21 | 69 | willful patent infringement. The patents-at-issue are U.S. Patent Nos. 8,466,159 (“the ’159 patent”), 8,492,386…8,492,386 (“the ’386 patent”), 8,680,106 (“the ’106 patent”), 8,685,984 (“the ’984 patent”), and 8,809,265…the ’265 patent”)1. Gilead alleges that the ’159, ’386, ’106, ’984, and ’265 patents are invalid…consolidated action with claims for declaratory relief of patent invalidity and unenforceability and state law …infringement of the ’159, ’386, ’106, ’984, and ’265 patents by marketing and sale of Gilead’s fixed dose combination | External link to document | |
2015-03-13 | 86 | #39;s first two patent applications-Patent Nos. 8,466,159 (the"' 159 patent") and 8,492,386…quot;386 patent"). (Id.,~ 150.) Later that day, after it learned of the issued patents, Gilead …December 9, 2013, the European Patent Office rejected AbbVie's pending patent applications for the Combination…(collectively, "Gilead") brought this patent infringement suit against defendants Abbott Laboratories…AbbVie falsely and knowingly represented to the U.S. Patent and Trademark Office ("PTO") that it | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |